R de Cássia Viu Carrara1,2, A M Fontes3,4, K J Abraham5, M D Orellana3, S K Haddad3, P V B Palma3, R A Panepucci3, M A Zago3,6, D T Covas3,6. 1. Center for Cell-Based Therapy of the Regional Blood Center of Ribeirão Preto, Avenida Tenente Catao Roxo, 2501, Monte Alegre, Ribeirao Preto, Sao Paulo, 14051-140, Brazil. rcvcarrara@hotmail.com. 2. UNAERP, Avenida Costábile Romano, 2201, Ribeirania, Ribeirao Preto, Sao Paulo, 14096-900, Brazil. rcvcarrara@hotmail.com. 3. Center for Cell-Based Therapy of the Regional Blood Center of Ribeirão Preto, Avenida Tenente Catao Roxo, 2501, Monte Alegre, Ribeirao Preto, Sao Paulo, 14051-140, Brazil. 4. Department of Genetics, Medical School of Ribeirão Preto, University of São Paulo, Avenida Bandeirantes, 3900, Monte Alegre, Ribeirao Preto, Sao Paulo, 14049-900, Brazil. 5. Department of Puericulture and Pediatrics, Medical School of Ribeirão Preto, University of São Paulo, Avenida Bandeirantes, 3900, Monte Alegre, Ribeirao Preto, Sao Paulo, 14049-900, Brazil. 6. Department of Clinical Medicine, Medical School of Ribeirão Preto, University of São Paulo, Avenida Bandeirantes, 3900, Monte Alegre, Ribeirao Preto, Sao Paulo, 14049-900, Brazil.
Abstract
PURPOSE: The fusion gene BCR-ABL has an important role to the progression of chronic myeloid leukemia (CML) and several signaling pathways have been characterized as responsible for the terminal blastic phase (BP). However, the initial phase, the chronic phase (CP), is long lasting and there is much yet to be understood about the critical role of BCR-ABL in this phase. This study aims to evaluate transcriptional deregulation in CD34+ hematopoietic cells (CD34+ cells) from patients with untreated newly diagnosed CML compared with CD34+HC from healthy controls. METHODS: Gene expression profiling in CML-CD34 cells and CD34 cells from healthy controls were used for this purpose with emphasis on five main pathways important for enhanced proliferation/survival, enhanced self-renewal and block of myeloid differentiation. RESULTS: We found 835 genes with changed expression levels (fold change ≥ ±2) in CML-CD34 cells compared with CD34 cells. These include genes belonging to PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways. Four of these pathways converge to MYC activation. We also identified five transcripts upregulated in CD34-CML patients named OSBPL9, MEK2, p90RSK, TCF4 and FZD7 that can be potential biomarkers in CD34-CML-CP. CONCLUSION: We show several mRNAs up- or downregulated in CD34-CML during the chronic phase.
PURPOSE: The fusion gene BCR-ABL has an important role to the progression of chronic myeloid leukemia (CML) and several signaling pathways have been characterized as responsible for the terminal blastic phase (BP). However, the initial phase, the chronic phase (CP), is long lasting and there is much yet to be understood about the critical role of BCR-ABL in this phase. This study aims to evaluate transcriptional deregulation in CD34+ hematopoietic cells (CD34+ cells) from patients with untreated newly diagnosed CML compared with CD34+HC from healthy controls. METHODS: Gene expression profiling in CML-CD34 cells and CD34 cells from healthy controls were used for this purpose with emphasis on five main pathways important for enhanced proliferation/survival, enhanced self-renewal and block of myeloid differentiation. RESULTS: We found 835 genes with changed expression levels (fold change ≥ ±2) in CML-CD34 cells compared with CD34 cells. These include genes belonging to PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways. Four of these pathways converge to MYC activation. We also identified five transcripts upregulated in CD34-CML patients named OSBPL9, MEK2, p90RSK, TCF4 and FZD7 that can be potential biomarkers in CD34-CML-CP. CONCLUSION: We show several mRNAs up- or downregulated in CD34-CML during the chronic phase.
Authors: Katerina Machova Polakova; Vojtech Kulvait; Adela Benesova; Jana Linhartova; Hana Klamova; Monika Jaruskova; Caterina de Benedittis; Torsten Haferlach; Michele Baccarani; Giovanni Martinelli; Tomas Stopka; Thomas Ernst; Andreas Hochhaus; Alexander Kohlmann; Simona Soverini Journal: J Cancer Res Clin Oncol Date: 2014-11-04 Impact factor: 4.553
Authors: P Fallah; N Amirizadeh; B Poopak; G Toogeh; E Arefian; F Kohram; S M A Hosseini Rad; M Kohram; H Teimori Naghadeh; M Soleimani Journal: Int J Lab Hematol Date: 2015-04-02 Impact factor: 2.877
Authors: E Diaz-Blanco; I Bruns; F Neumann; J C Fischer; T Graef; M Rosskopf; B Brors; S Pechtel; S Bork; A Koch; A Baer; U-P Rohr; G Kobbe; A von Haeseler; N Gattermann; R Haas; R Kronenwett Journal: Leukemia Date: 2007-01-25 Impact factor: 11.528
Authors: J E Sokal; E B Cox; M Baccarani; S Tura; G A Gomez; J E Robertson; C Y Tso; T J Braun; B D Clarkson; F Cervantes Journal: Blood Date: 1984-04 Impact factor: 22.113
Authors: Geert C van Almen; Wouter Verhesen; Rick E W van Leeuwen; Mathijs van de Vrie; Casper Eurlings; Mark W M Schellings; Melissa Swinnen; Jack P M Cleutjens; Marc A M J van Zandvoort; Stephane Heymans; Blanche Schroen Journal: Aging Cell Date: 2011-05-25 Impact factor: 9.304